pMDI Triple Inhaler Only

PreclinicalSmall molecule

FFirst Affiliated Hospital of Ningbo University

pMDI Triple Inhaler Only is one of 27 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseRecruiting

Chronic Obstructive Pulmonary DiseasePreclinical

Recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

26 2

Flovent

GSK

Preclinical

6 3

Spiriva

Boehringer Ingelheim

Preclinical

15 4

Aclidinium Bromide

AstraZeneca

Preclinical

21 5

Duragesic

CCephalon

Preclinical

2 6

Coumadin

AAbbott

Preclinical

1 7

Narcan

SScienture

Preclinical

1 8

Zoloft

VViatris Specialty LLC

Preclinical

1 9

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Antibiotic

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Chronic Obstructive Pulmonary Disease

NCT07030881

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy: A Multicenter Randomized Controlled Trial

Recruiting·FFirst Affiliated Hospital of Ningbo University·Preclinical·NCT07030881·380 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pMDI Triple Inhaler Only. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pMDI Triple Inhaler Only compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pMDI Triple Inhaler Only. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Ningbo University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFirst Affiliated Hospital of Ningbo University

pMDI Triple Inhaler Only

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

References

Drug Info

Quick Facts

Related News